haloperidol decanoate LAI
Selected indexed studies
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. (CNS Drugs, 2021) [PMID:33507525]
- Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. (Psychiatr Serv, 2016) [PMID:27247177]
- Long-acting injectable antipsychotics in the treatment of schizoaffective disorder: A retrospective mirror image study for hospitalizations and treatment costs. (Asian J Psychiatr, 2025) [PMID:40664011]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. (2021) pubmed
- Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). (2013) pubmed
- Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. (2016) pubmed
- Long-acting injectable antipsychotics in the treatment of schizoaffective disorder: A retrospective mirror image study for hospitalizations and treatment costs. (2025) pubmed
- Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. (2018) pubmed
- Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. (2014) pubmed
- Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. (2005) pubmed
- Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study. (2019) pubmed
- Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. (2018) pubmed
- Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. (2016) pubmed